JHU-083

JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b+ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals[1][2].

Product Specifications

CAS Number

[1998725-11-3]

UNSPSC

12352211

Target

Glutaminase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/jhu-083.html

Purity

99.38

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OCC)[C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CC(C)C)N)=O

Molecular Formula

C14H24N4O4

Molecular Weight

312.36

References & Citations

[1]Zhu X, et al. JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress. Neuropsychopharmacology. 2019 Mar;44 (4) :683-694.|[2]Riggle BA, et al. MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice. Proc Natl Acad Sci U S A. 2018 Dec 18;115 (51) :E12024-E12033.